Zacks: Brokerages Expect Can-Fite Biopharma Ltd (CANF) to Post -$0.04 Earnings Per Share

Share on StockTwits

Wall Street analysts expect that Can-Fite Biopharma Ltd (NASDAQ:CANF) will announce earnings of ($0.04) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma also posted earnings of ($0.04) per share in the same quarter last year. The business is scheduled to announce its next earnings report on Monday, November 26th.

According to Zacks, analysts expect that Can-Fite Biopharma will report full-year earnings of ($0.16) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.24) per share. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Can-Fite Biopharma.

Can-Fite Biopharma (NASDAQ:CANF) last posted its quarterly earnings results on Friday, August 31st. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $2.00 million.

CANF stock traded down $0.03 during trading on Wednesday, reaching $1.29. 25,366 shares of the stock traded hands, compared to its average volume of 153,397. Can-Fite Biopharma has a 52-week low of $1.12 and a 52-week high of $2.75.

About Can-Fite Biopharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Read More: Moving Average (MA)

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply